2Aberer W, Kranke B. One-year treatment ofchronic urticaria with mizolastine:efficacyand safety [ J ]. J Eur Acad Dermatol Venereol,2000,14:83 -90.
3Henderson WR Jr,Tang LO,Chu SJ,et al. A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma modle[ J]. Am J Respir Crit Care MED,2002,165 (10): 108-116).
2Pichat P;Angel I;Arbilla S.Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat,1998(01).
3Benavides J;Schoemaker H;Dana C.In vivo and in vitro interaction of the novel selective histamine H1 receptor antagonist mizolastine with H1 receptors in the rodent,1995.
4Dubertr;Murrieta Aguttes M;Tonet J.Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria:results of the MILOR Study[J],1999.
5Sabbah A;Daele J;Wade AG.Comparison of the efficacy,safety,and onset of action of mizolastine,cetirizine,and placebo in the management of seasonal allergic rhinoconjunctivitis.MIZOCET Study Group[J],1999.
6Leynadier F;Duarte-Risselin C;Murrieta M.Comparative therapeutic effect and safety of mizolastine and loratadine in chronic idiopathic urticaria URTILOR study group,2000.
6Zechel H J, Brock N, Lenke D, et al. Pharmacological and toxicological properties of azelastine, a novel antiallergic agent[ J]. Arzneimittelforschung, 1981,31 (8) : 1184 - 1193.
7Henz BM, Metzenauer P, O' Keefe E, et al. Differential effects of new-generation Hi-receptor antagonists in pruritic dermato- ses[J]. Allergy, 1998, 53(2): 180- 183.
8Suzuki Y, Ra C. Analysis of the mecha-nism for the development of allergic skin in- flammation and the application for its treat- ment: aspirin modulation of IgE-dependent mast cell activation : role of aspirin-induced exacerbation of immediate allergy [ J ]. J Pharmacol Sci, 2009,110 ( 3 ) : 237 - 244.
9Hay DW. Pharmacology of leukotriene re- ceptor antagonists. More than inhibitors of bronchoeonstriction[ J]. Chest, 1997 , 111 (2) : 35S-45S.
10Wan KS. Efficacy of leukotriene receptor antagonist with an anti-H1 receptor antag- onist for treatment of chronic idiopathic ur- ticaria[ J ]. J Dermatolog Treat, 2009,20 (4) : 194 - 197.
